Showing 121 - 140 results of 33,847 for search '(( 5 non decrease ) OR ((( a point decrease ) OR ( 50 ((mean decrease) OR (a decrease)) ))))', query time: 0.92s Refine Results
  1. 121
  2. 122
  3. 123

    HFD induces LDs and decreases ER and mitochondria in nephrocytes. by Aleksandra Lubojemska (10746241)

    Published 2021
    “…(<b>E</b>) Low and high magnification views of pericardial nephrocytes (dotted outlines) from STD and HFD larvae, showing that HFD decreases mitochondria (marked with anti-ATP5A) and ER (marked with anti-KDEL) but increases LDs (marked with LipidTOX). …”
  4. 124

    Data_Sheet_1_Effectiveness of non-pharmaceutical interventions in nine fields of activity to decrease SARS-CoV-2 transmission (Spain, September 2020–May 2021).PDF by Inés Barbeito (5864351)

    Published 2023
    “…Background<p>We estimated the association between the level of restriction in nine different fields of activity and SARS-CoV-2 transmissibility in Spain, from 15 September 2020 to 9 May 2021.</p>Methods<p>A stringency index (0–1) was created for each Spanish province (n = 50) daily. …”
  5. 125
  6. 126
  7. 127

    Inclusion of SRRM4-regulated exons is decreased in tumors and cancer cell lines. by Sarah A. Head (6066398)

    Published 2021
    “…(B) SRRM4 target exons with respect to their average PSI in normal tissues. Red points are exons with PSI decreasing by at least 5% in at least 1 tumor type. …”
  8. 128
  9. 129
  10. 130
  11. 131
  12. 132
  13. 133
  14. 134
  15. 135
  16. 136

    Table 1_Previous treatment decreases efficacy of pralsetinib in RET fusion-positive non-small-cell lung cancer.doc by Lei Wang (6656)

    Published 2025
    “…Background<p>Pralsetinib is a selective RET inhibitor. The ARROW trial revealed that RET fusion-positive non-small-cell lung cancer (NSCLC) can benefit from pralsetinib with tolerable adverse events (AEs). …”
  17. 137
  18. 138
  19. 139
  20. 140